CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · General Reference

Merigolix

pharmaceutical compound

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionAug 21, 2026
Entity authorityQ133252468 ↗
Source-derived summary

Merigolix (INNTooltip International Nonproprietary Name; developmental code names HS-10518, NCE-403, SKI-2670, TU-2670) is a gonadotropin releasing hormone (GnRH) antagonist which is under development for the treatment of endometriosis and uterine fibroids. It is taken by mouth. The drug is being developed by TiumBio, Daewon Pharmaceutical, and Jiangsu Hansoh Pharmaceutical. As of October 2024, it is in phase 2 clinical trials for both endometriosis and uterine fibroids.

Editorial summary

“Merigolix” enters the record as pharmaceutical compound. Crown Archives preserves that source wording while asking what Merigolix, pharmaceutical and compound can confirm, complicate or overturn.

Editorial reviewA dependable orientation record for establishing vocabulary, names and a first evidence trail. The current lead gives the account dated anchors—2024—that can be checked directly. The selected authority fields contribute no independent date. Its strongest next move is a source search built around Merigolix, pharmaceutical and compound.
Editorial analysis

Why this record matters

“Merigolix” is worth following because a concise public description often conceals a longer documentary argument. Here, Merigolix, pharmaceutical and compound provides the most credible route into that argument.

Evidence profile

Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated Aug 21, 2026. The linked authority identifier is Q133252468. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2024.

Critical limits

The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “Merigolix”, its source revision and the description used here.
  2. Expand the search: follow Merigolix primary sources, Merigolix archive and Merigolix research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “Merigolix”?
  2. What terminology or title could unlock a more precise catalogue search?
  3. Which institution is responsible for the underlying evidence?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “Merigolix” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.